A gene‑expression‑based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations
- 2 December 2019
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 19 (1) , 1060-1065
Abstract
The demonstration of tissue invasion by histology is an essential criterion for the differential diagnosis of benign and malignant mesothelial proliferations. When tissue invasion cannot be identified, the use of ancillary tests is sometimes necessary. Among investigated markers, the loss of BRCA1 associated protein 1 (BAP1) protein expression and the homozygous deletion of p16 have shown 100% specificity in separating benign and malignant mesothelial lesions. However, beyond the excellent specificity of these two markers, their low sensitivity limits their clinical utility. In this context, a previous study developed and tested a novel tool for use in the differential diagnosis of malignant pleural mesothelioma (MPM) using the NanoString System and a classification algorithm. In the current study, the performance of gene classifiers were compared using BAP1 and p16 testing. p16 FISH and BAP1 immunohistochemistry were performed on the same series of 34 epithelioid MPM and 20 benign pleural lesions, which were previously analyzed by the system. The diagnostic performance of p16, BAP1 and our classification models were compared using ROC analysis. It was observed that BAP1 loss and p16 deletion were highly specific for MPM, since they were not detected in benign lesions. However, their AUC values were not completely satisfying (BAP1: 0.8235; p16: 0.7647) particularly due to their low sensitivities. As expected, combining BAP1 and p16 tests increased the diagnostic sensitivity, thus improving the AUC (0.8824). In the same series of cases, our MPM tool outperformed BAP1 and p16 tests using the 22 and 40‑gene classification models (AUC 22‑gene model: 0.9996; AUC 40‑gene model: 0.9990). In conclusion, the present gene‑expression‑based classification exhibited great potential and further validation is required to support these findings in a prospective fashion, in order to provide a solid alternative for pleural proliferation diagnosis.Keywords
This publication has 29 references indexed in Scilit:
- Mesothelial ProliferationsAmerican Journal of Clinical Pathology, 2014
- Molecular pathogenesis of malignant mesotheliomaCarcinogenesis, 2013
- The Diagnostic Utility ofp16FISH and GLUT-1 Immunohistochemical Analysis in Mesothelial ProliferationsAmerican Journal of Clinical Pathology, 2011
- FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesotheliomaJournal of Clinical Pathology, 2010
- Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaEuropean Respiratory Journal, 2009
- Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomasVirchows Archiv, 2008
- Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomasLaboratory Investigation, 2008
- Implications of P16/CDKN2A deletion in pleural mesotheliomasLung Cancer, 2005
- The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusionsCancer, 2002
- The Separation of Benign and Malignant Mesothelial ProliferationsAmerican Journal of Surgical Pathology, 2000